Study S001192

A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of IBI362 in Chinese Obese Adolescent Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06536023
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 36
Start: 2024-08-30
Primary completion: 2025-07-22
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Adolescents With Obesity
Interventions: DRUG:IBI362; DRUG:IBI362 placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Incidence of adverse events and serious adverse events [up to week 20]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0054780	1133-OR: Safety, Tolerability, and Pharmacokinetics of Once-Weekly Mazdutide in Chinese Adolescents with Obesity: A Phase 1b Trial CHUNXIU GONG, Diabetes	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06536023